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Rheumatoid arthritis (RA) is a progressive, destructive autoimmune arthritis. Break of
tolerance and formation of autoantibodies occur years before arthritis. Adaptive immunity
is initiated in lymphoid tissue where lymph node stromal cells (LNSCs) play a crucial
role in shaping the immune response and maintaining peripheral tolerance. Here we
performed the first epigenomic characterization of LNSCs during health and early RA,
by analyzing their transcriptome and DNA methylome in LNSCs isolated from lymph
node needle biopsies obtained from healthy controls (HC), autoantibody positive RA-risk
individuals and patients with established RA. Of interest, LNSCs from RA-risk individuals
and RA patients revealed a common significantly differential expressed gene signature
compared with HC LNSCs. Pathway analysis of this common signature showed, among
others, significant enrichment of pathways affecting the extracellular matrix (ECM),
cholesterol biosynthesis and immune system. In a gel contraction assay LNSCs from
RA-risk individuals and RA patients showed impaired collagen contraction compared
to healthy LNSCs. In RA LNSCs a significant enrichment was observed for genes
involved in cytokine signaling, hemostasis and packaging of telomere ends. In contrast, in
RA-risk LNSCs pathways in cancer (cell cycle related genes) were differentially expressed
compared with HC, which could be validated in vitro using a proliferation assay, which
indicated a slower proliferation rate. DNA methylation analyses revealed common and
specific differentially methylated CpG sites (DMS) in LNSC from RA patients and RA-risk
individuals compared with HC. Intriguingly, shared DMS were all associated with antigen
processing and presentation. This data point toward alterations in cytoskeleton and
antigen-processing and presentation in LNSC from RA-risk individuals and RA patients.
Further studies are required to investigate the consequence of this LNSC abnormality on
LNSC-mediated immunomodulation.
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INTRODUCTION
Rheumatoid arthritis (RA) is a progressive, destructive
autoimmune disease of which the etiology is only partly
understood. RA-specific autoantibodies as rheumatoid factor
(RF) and anti-citrullinated protein antibodies (ACPAs) (1) can
be present years before the manifestation of clinical disease (2)
and during this RA-risk phase (3) synovial inflammation seems
absent (4, 5), suggesting that possibly yet unidentified immune
processes taking place outside of the synovium might promote
disease development.
Since (auto-) antibody production and peripheral tolerance
are initiated and maintained within secondary lymphoid
organs, the lymph nodes (LN) stand out as promising extra-
synovial target for investigation. In line with findings in
mice, showing LN activation before onset of arthritis (6),
we recently reported altered frequencies of B cells, T cell
subsets and innate lymphoid cell subsets in LN biopsies of
RA-risk and early-stage RA patients compared to healthy
controls (7, 8).
Studies in mice revealed that lymph node stromal cells
(LNSCs) are crucial regulators of adaptive immunity and
highlighted their various abilities to shape T and B cell
responses (9, 10). They also orchestrate trafficking of immune
cells within the LN (11, 12), control lymphocyte activation,
differentiation and survival (9), but can also inhibit T
cell proliferation (13, 14) and maintain peripheral tolerance
(13, 15). LNSCs comprise the CD31-expressing lymphatic
endothelial cells (LECs) and blood endothelial cells (BECs) and
the CD31 negative fibroblastic reticular cells (FRCs), which
express podoplanin. According to their localization in the
LN, FRCs can be further separated into marginal reticular
cells (MRCs) and T-zone reticular cells (TRCs). In addition
double-negative cells (DNCs) neither expressing CD31 nor
podoplanin were described. This group of LNSCs contains
follicular dendritic cells (FDCs) and other, less well described
LNSC subtypes.
Since LNSCs have mainly been studied in mice, we
developed an experimental model to allow research on
human LNSCs (16). We recently reported clear disturbances
in the microenvironment early in development of systemic
autoimmunity (14, 16). LNSCs cultured from autoantibody
positive individuals at risk of developing RA (RA-risk group)
and RA patients showed reduced induction of chemokines
and their capacity to regulate T cell proliferation seemed
diminished (14, 16). Accordingly, due to their impact on
immunity and tolerance, we hypothesize that malfunctioning
of LNSCs leads to a microenvironment where immune
responses are not properly controlled leading to activation of
(autoreactive) lymphocytes and production of autoantibodies.
Here we studied human LNSCs on a detailed molecular
level by analyzing their genome-wide transcriptome and
methylome profile during health and the earliest phases
of RA to pinpoint epigenetic changes ongoing in systemic
autoimmunity and to potentially identify new and unanticipated
therapeutic targets.
RESULTS
Molecular Cell Subsets of Expanded
Human LNSCs in Culture
To study the molecular subtype of expanded human LNSCs,
we first compared the measured expression profile with a
transcriptional profile that was shown to differentiate FRCs,
DNCs, LECs, and BECs in freshly isolated murine LNSCs (9).
Based on gene expression of the human LNSCs, 12 out of 15
samples expressed podoplanin (PDPN), which differentiates
FRCs (PDPN+) from DNCs (PDPN-) (Figure 1A).Flow
cytometry analysis of CD31, CD45, and podoplanin (gp38)
showed that the cultured human LNCS consisted of a mixed
population of FRCs and DNCs with some variability in the
proportion of each subtype, as also shown in our previous study
(16) (Supplementary Figure 1).
Human LNSCs transcriptional profiles matched data from
murine studies where FRCs and DNCs in contrast to BECs
lack expression of von Willebrand factor (vWF), and selectin
P (SELP), and in contrast to BECs and LECs lack expression
of Tyrosine kinase with immunoglobulin-like and EGF-like
domains 1 (TIE1), cadherin 5 (CDH5), CD31 (PECAM1), Fms-
related tyrosine kinase 4 (FLT4), Lymphatic Vessel Endothelial
Hyaluronan Receptor 1 (LYVE1), and Prospero homeobox
protein 1 (PROX1) with clear expression of platelet-derived
growth factor receptor (PDGFR) A and B, desmin and alpha-
actin 2 (ACTA2). In contrast to the freshly isolated mouse LNSC,
in the cultured human LNSC we found clear transcript levels
of the Angiopoietin-1 receptor (TEK). Furthermore, none of
the samples expressed CCL19 and CCL21 (Figure 1A), which
might be due to the absence of external stimuli or contact
with lymphocytes in in vitro cultured human LNSCs. Indeed, in
an earlier study we showed that expanded human LNSCs are
capable of producing these key chemokines upon stimulation,
with lower induction observed in RA LNSCs (16). Overall, the
transcriptional profile of in vitro expanded human LNSCs largely
overlapped with the reported profile of mouse FRCs.
Recently, Rodda et al. looked into the cellular heterogeneity of
murine peripheral LN (pLN) non-endothelial SCs using single-
cell RNA sequencing (scRNAseq) (17). In this study, known cell
types within the stromal cells family were identified, such as
FDCs, MRCs, perivascular cells (PvCs), and TRCs. Importantly,
this study identified 10 top-ranked genes differentially expressed
between the above listed subtypes (Supplementary Table 1).
From this analysis the TRC could be further discriminated into
other subtypes called Ccl19high, Ccl18low, Cxcl9+, CD34+. The
other two subtypes identified and named Inmt+ and Nra4+,
could not be uniquely coupled to a described type of stromal cells
(17).Further studies are needed to outline the function of these
specific stromal cell subsets.
We investigated whether these subset specific gene signatures
were expressed in our cultured human LNSCs (Figure 1B
and Supplementary Table 2). The heatmap shows that many
genes of the nine reported cell subsets are low expressed.
As expected, our bulk LNSCs in culture do not contain
FDCs, MRCs, and perivascular cells (PvCs), as these cells
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FIGURE 1 | Key LNSC gene signature in human cells. (A) Heat map of expression data for genes characteristic for LNSCs as reported in mice is shown. Colors
represent column-centered Z-scores of normalized read counts. Red is high, blue is low expression. (B) Different cell subsets present in bulk human LNSC cultures.
The expression of the top 10 differentially expressed genes of each described murine LNSC subset (17) was investigated in the expanded human LNSCs. A heat map
was obtained using the variance stabilizing transformation of the raw counts. The color scale indicates the low expressed genes (dark blue) up to the high expressed
genes (dark red). Each column represents a donor, and each row refers to a gene. On the far right, the cell subset is given next to their related gene signature. The
percentage indicates the proportion of genes in the subset signature expressed by our human LNSCs. (C) Propplot of the estimated cell subset distribution in cultured
human LNSC. An NMF-class object that contains proportions as its mixture coefficient matrix (M). Each column refers to a donor. At the bottom of the column from
left to right, healthy individuals (H), RA-risk individuals (A), rheumatoid arthritis patients (RA). The colors correspond to the different cell subsets: CD34 (blue),
CCL19low (green), INMT (red), NR4A1 (gray).
are lost during culturing. We next selected those cell subsets
retaining more than 60% of the genes from the gene signature:
CD34, INMT, CCL19low, and NR4A1 (Supplementary Table 2).
Computational deconvolution (18) of global gene expression in
our dataset suggests that our expanded LNSCs in culture mostly
consists of the CD34, INMT, the CCL19low subsets, and NR4A1
cells (Figure 1C and Supplementary Figure 2). Looking at the
expression of the gene set that was used by Malhotra et al. to
define LNSC subsets, in the Rodda study showed that similar to
the cultured human LNSCs, CD34, Inmt, Ccl19low, and Nr4a1
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murine cells are characterized by low expression of Ccl19 and
high expression of PDGFRA in contrast to the other SC subsets.
Healthy controls, RA-risk individuals and RA patients show
no differential frequency of these cell subsets. This latter suggests
that the original environment of LNSC (healthy, RA-risk or
RA) do not determine the preferential outgrowth of one subset
over another and that potential differences between donors are
probably unrelated to differences in cell subsets present.
Transcriptional Changes in RA-Risk and RA
LNSCs When Compared to Healthy LNSCs
Next we compared the transcriptional profiles of healthy (HC,
n = 5), ACPA + RA-risk (n = 6), and RA (n = 4) LNSCs using
RNA sequencing. Despite being limited by a small number of
LNSC donors, this explorative analysis revealed genes that were
significantly differentially expressed in LNSCs from RA/RA-risk
individuals compared with HC. One-way hierarchical clustering
based on the most significantly differentially expressed genes
between the groups (FDR < 5%, fold change ± 0.5, and mean
expression > 50) indicated that RA/RA-risk LNSCs displayed a
distinct expression profile compared to healthy control LNSC,
while LNSCs from RA-risk individuals and RA patients were
more similar to each other (Figure 2A). This became particularly
clear when analyzing the overlap in differentially expressed genes
(based on P < 0.05, fold change ± 0.5, and mean expression
> 50) between the three study group comparisons (Figure 2B).
The Venn diagram revealed only minor differences between
LNSCs fromRA-risk patients when compared to LNSCs from RA
patients (66 genes).
In contrast, quite a high number of genes were differentially
expressed either specifically in RA (450) or RA-risk (549)
LNSCs or in both (473) when compared to HC. Genes that
were only significantly changed in healthy vs. RA or healthy
vs. RA-risk, but were still not significantly changed in the
RA/RA-risk comparison, usually showed a change in the same
direction, but did not reach statistical significance according
to our cut-offs (p < 0.05, fold change ± 0.5, and expression
> 50 in all measured samples). These numbers thus underline
the similarity of RA-risk and RA LNSCs. Pathway analysis
of the commonly differentially expressed genes in RA/RA-risk
LNSCs showed, among others, significant enrichment of genes
encoding for proteins or regulators involved in extracellular
matrix (ECM) including many genes involved in the actin
cytoskeleton (Figure 2B). To validate and interpret this finding a
gel contraction assay was performed which revealed that LNSCs
from RA-risk individuals and RA patients showed impaired
collagen contraction compared to HC (Figures 3A,B). The gels
containing healthy LNSCs (n = 5) covered 26.5% ±2.5 of the
well, while RA-risk (n= 4) and RA (n= 5) LNSC only contracted
the gels to 33.9% ±5.9 and 30.6% ±6.5, respectively (Figure 3B
representative picture).
Other common significantly enriched genes were,
amongst others, involved in cholesterol biosynthesis and
the immune system.
Of the transcripts that were differentially expressed specifically
in either RA-risk or RA LNSCs when compared to healthy
LNSCs, gene-set analyses showed similar enrichment of
pathways associated with ECM and the immune system. RA
LNSCs specific enrichment involved pathways like Systemic
lupus erythematosus (e.g., C3), cytokine signaling (e.g., IL-7)
and packaging of telomere ends (e.g., histone cluster genes;
Figure 2B). In contrast, specific gene-sets enriched in RA-
risk LNSCs included pathways involved in cancer (e.g., cell
cycle related genes), MHC class II antigen presentation and
focal adhesion.
To confirm specific differences in RA-risk LNSCs on
a functional level, we analyzed adhesion, spreading, and
proliferation of LNSCs using the xCelligence system, which
measures cell growth viability in real time during culture (19).
When focusing on the proliferation phase, RA-risk LNSCs
proliferated slower compared to healthy controls (Figures 3C,D
and Supplementary Figure 3). This finding could be confirmed
by determination of the cell numbers after 48 h of cell
culture (Figure 3E).
Collectively, compared with healthy controls, LNSCs from
RA-risk individuals and RA patients displayed a different
transcriptional gene expression profile indicating altered
proliferation and contraction of LNSCs in RA-risk and RA
patients, respectively.
Differences in DNA Methylation in RA
(-Risk) LNSCs
DNA methylation analyses uncovered 279 significantly
differentially methylated CpG sites (DMS) in LNSCs from
RA patients (n = 5) vs. HC (n = 4), 318 DMS between RA-risk
individuals (n = 3) vs. HC, and 511 DMS when comparing RA
patients with RA-risk individuals (mean beta value differences
of 0.1, p > 0.05). One-way hierarchical clustering of the top 20
CpG gene sites (top 10 with mean beta value difference of above
0.3 are defined methylated and top 10 with −0.3 are defined
unmethylated) per comparison in a heatmap clearly shows
different DMS patterns between healthy, RA-risk and RA LNSCs
(Figure 4A).
Key immune related genes showing different methylation
patterns included IL-6R and HLA-DR. Next, we again plotted
the DMS into a Venn diagram to indicate common and
specific DMS (Figure 4B). Six DMS (SLC27A2, CSMD1, LMNA,
INF2, GRIN2A, FNDC3B) were identified that were commonly
differential in RA/RA-risk vs. healthy LNSCs but also different
between RA and RA-risk LNSCs. Pathway analysis on specific
DMS in RA LNSCs showed again an enrichment of regions
involved in ECM and hemostasis whereas in RA-risk LNSCs no
significant enrichment could be detected. Twenty seven DMS
were different in both RA and RA-risk LNSCs compared to
healthy LNSC. Eighty percent of all DMS were significantly
hypomethylated and pathway analyses showed that these DMS
are mostly involved in antigen processing and presentation as
they include HLA-DR gene regions.
We next investigated the expression levels of HLA-DRA
mRNA in our cultured LNSCs. Under homeostatic conditions
HLA-DRA was expressed at low levels, with a trend toward lower
levels in RA LNSCs (Figure 5A). To check the surface expression
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FIGURE 2 | Transcriptomic analysis of human LNSCs. (A) Cluster diagram representing the most significantly differentially expressed genes in LNSC when comparing
RA(-risk) with healthy controls using an FDR q < 0.05. Colors represent Z-scores of normalized read counts (row-scaling). Red is high, blue is low expression. (B) Venn
diagram indicating significantly differentially expressed genes between the 3 study groups using a cutoff of P < 0.05, log2 fold change >0.5, and a mean expression
>50. Subsequently, the Molecular Signature Database was used to compute the overlap between the obtained significantly differentially expressed gene lists and
gene lists in well-described pathway databases (Canonical pathways, KEGG, Biocarta, and Reactome). The top 10 pathways are listed with an FDR q < 0.05.
FIGURE 3 | Functional assays supporting findings of transcriptional profiling. (A) Contraction assay. Cells were seeded in collagen gels and gels released after 48 h.
Contraction of gel was measured after 20 h. (B) Representative picture of contraction assay. (C) Proliferation of LNSCs was analyzed using the xCelligence system
which measures adhesion, spreading and proliferation in real time during culture. Picture shown is focusing on the proliferation phase starting 27 h after seeding (see
also Supplementary Figure 3). RA-risk LNSCs proliferated slower compared to healthy controls. (D) Quantification of results shown in (C). (E) Cell counting kit-8:
Cells were seeded at equal numbers and the amount of formazan dye, generated by dehydrogenase activity in cells and being proportional to the amount of living
cells, was measured after 48 h. *p < 0.05.
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FIGURE 4 | DNA methylome profiles of human LNSCs. (A) Cluster diagram representing the most significantly differentially expressed genes in LNSC when
comparing RA(-risk) with healthy controls. Plotted are the beta values of the top 20 CpG gene sites (top 10 genes with mean average beta values above 0.3 are
methylated in red and top 10 genes with mean average beta values of above −0.3 delta are unmethylated in blue) per comparison. (B) Venn diagram indicating
significantly differentially methylated CpG sites between the 3 study groups using a cutoff mean beta value differences of 0.1 and p-values below 0.05. Subsequently,
the Molecular Signature Database was used to compute the overlap between the obtained significantly differentially methylated CpG gene sites and gene lists in
well-described pathway databases (Canonical pathways, KEGG, Biocarta, and Reactome). If present, the top 10 pathways are listed with an FDR q < 0.05.
of HLA-DR on our expanded LNSCs we stimulated our cells
with IFNγ, which has been described to upregulate HLA-DR
on LNSCs (20, 21). Flow cytometry revealed that only a minor
frequency of unstimulated LNSCs expressed HLA-DR on their
surface (22), while IFNγ stimulation rapidly induced HLA-DR
(Figure 5B) with similar levels in RA/RA-risk LNSCs and healthy
LNSCs (data not shown).
Overall, this data reveals epigenetic imprinting of LNSCs
during the earliest phases of RA.
DISCUSSION
In this explorative study, we characterized for the first time
the epigenomic landscape of human LNSCs during health and
systemic autoimmunity. We demonstrate that cultured human
LNSCs show a comparable expression profile to mouse LNSCs,
suggesting that the reported functional role of mouse LNSCs
is potentially also operational in humans. Furthermore, our
findings clearly highlight that RA-risk and RA LNSCs are more
comparable to each other than to healthy control LNSCs and that
epigenetic changes already occur in autoantibody positive RA-
risk individuals. Therefore, LNSCs seem to obtain an epigenetic
imprint during systemic autoimmunity, which may play an
important role in RA development.
Deconvolution analysis was performed to determine if the
recently discovered murine LNSC subsets (17) could be present
in our expanded human LNSCs based on bulk RNA sequencing
data. The analysis shows that the expanded human LNSCs
contains an heterogeneous population of LNSC subsets, where,
based on the molecular profile, the so called INMT, CD34, and
CCL19low are most predominant but also a low frequency of
NR4A1 cells could be detected. The estimated frequency of the
cell subsets was similar between LNSCs expanded from healthy
controls and RA (-risk) individuals. This finding suggests that
in our experimental setting the disease status does not promote
the outgrowth of one subset of another one. However, we do
not exclude that in vivo the disease status may affect the cell
proliferation differently.
Our findings reveal disturbances within the LN
microenvironment, which are in line with our earlier studies
(8, 14, 16, 23, 24) and with reports showing defects of the
stromal compartment within the bone marrow (BM), another
very specialized niche next to the LN. For RA several defects
in the BM in stromal but also in hematopoietic cells have been
reported (25, 26). The frequency of polyreactive antibodies
found in naïve B cells is higher in RA than in healthy controls
suggesting a defect B cell central tolerance checkpoint within
the BM (25). In addition, long-term cultures of mononuclear
cells derived from BM aspirates from RA patients failed to
support normal haematopoiesis (27) and RA BM mesenchymal
stromal cells (BM MSCs) in culture produced less IL-7 (28).
Our findings indicate a decreased proliferation of LNSCs
in RA-risk compared with LNSCs from healthy controls.
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FIGURE 5 | Expression of HLA-DR by human LNSCs. (A) mRNA expression levels of HLA-DRA was assessed by qPCR and data is presented in Tukey boxplots
(healthy n = 7, RA-risk n = 8, RA n = 7). (B) Flow cytometry gating strategy used to identify CD45-CD31- stromal cells according to their podoplanin (gp38) and
HLA-DR (MHC class II) expression. Gating was based on negative isotype staining. Pictures display 1 representative donor out of 13 donors tested (healthy n = 5,
RA-risk n = 5, and RA n = 3). Numbers adjacent to the outlined areas indicate percentage of cells in the gated population.
Myeloid progenitor cells in RA BM are also less proliferative
compared to healthy controls (26). In addition in mouse
models of systemic lupus erythematosus (SLE), BM MSC have
a slower proliferation rate and differentiate less (29). Impaired
proliferation of RA-risk LNSCs might influence their immune-
modulatory activities.
Proliferation and contraction of LNSCs are important features
of stromal cells in order to regulate LN flexibility and integrity
during ongoing inflammation (30, 31). Expansion of LNs occurs
during an immune response to accommodate the increasing
number of lymphocytes, followed by contraction and return to
steady state. The initial expansion of the LN is greatly regulated
by the podoplanin-CLEC2 signaling axis. Podoplanin, which is
expressed on two subsets of LNSCs, FRCs, and the LECs, binds
to CLEC-2 on activated, infiltrating dendritic cells (DCs) which
leads to release of the stiffness of the FRC network, allowing
them to stretch and it also induces proliferation (32). In parallel
with FRCs, also lymphoid tissue inducer cells (LTi’s) proliferate
during infection as seen in mouse models using Lymphocytic
Choriomeningitis Virus (LCMV) (31). LTi’s in turn increase
their release of LTα1β2 needed for stromal cell maturation
and stimulates production of IL-7 by LNSCs (10, 31, 33, 34),
which drives LTi survival. Crosstalk between FRC and LTi’s is
essential to foster LN expansion, remodeling and restoration
after infection (35). A previous study in our lab indicates that
the number of LTis is decreased in LN biopsies of RA patients
and RA-risk individuals (8). Altogether, the reduced capacities
of RA-risk LNSCs to contract and proliferate and the reduced
numbers of LTis might hamper the function of the LNSCs during
immune responses. Accordingly, the LN microenvironment
in RA-risk might be less capable to cope with inflammatory
conditions. The more pronounced changes in contraction and
proliferation in RA-risk individuals compared to RA patients
might also reflect a normal activation reaction in at-risk LNSCs,
which is impaired in RA LNSCs. Further investigations and
functional analysis of LNSCs from acute immune activation
and chronic autoimmune activation are needed to clarify
these points.
DNA methylation analyses revealed several differentially
methylated CpG sites (DMS) in LNSCs from RA and RA-risk
compared to healthy LNSCs. Of interest, the most profound
differences between RA/RA-risk and healthy LNSCs were found
in hypomethylated DMS involved in antigen processing and
presentation pathways (HLA-DR gene regions). Under resting
conditions LNSCs have a higher expression of MHC class I and
II as well as antigen-processing machinery than skin fibroblast
(9), and LNSCs upregulate genes within the MHC class II
pathway during an immune response (9), which taken together
marks them as superior antigen presenters among fibroblasts.
Hypomethylation of CpGs makes the chromatin more accessible
and genes potentially easier and faster to transcribe. For instance,
if murine skin epithelial stem cells were primed earlier in
vivo by a tissue damage, epigenetic changes in the chromatin
surrounding stress response genes occurred. As a result, these
cells reactedmore rapidly to the next challenge (36). It is tempting
to speculate that LNSCs increase their antigen presentation
during systemic autoimmunity, based on epigenetic changes
introduced by a stimulus in the early, at-risk phase of the
disease. However, since antigen presentation in LNSCs is mainly
described to induce tolerance (34), further experiments are
needed to investigate whether LNSCs try to limit or induce
autoimmunity. Furthermore, we also observed clear differences
in DNAmethylation between RA-risk and RA LNSCs, suggesting
ongoing epigenetic changes during disease progression. This is in
line with data shown in synovial fibroblasts from RA patients,
where methylation patterns only partially overlapped between
patients with early RA and patients with long-term established
RA (37, 38). Accordingly, longer follow up experiments should
be performed to better delineate the role of epigenetic changes in
LNSCs during RA progression.
In conclusion, our explorative study shows clear changes in
the epigenetic and transcriptomic landscape of human LNSCs in
RA-associated autoimmunity. However, only a small number of
individuals have been analyzed and the variation between donors
is high, therefore these findings should be evaluated in a larger
cohort. Also further challenging mechanistic studies are required
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to investigate whether altered epigenetics in LNSCs fromRA/RA-
risk patients alter the function of these cells. Our approach
of characterizing LNSC during RA development has great
potential to reveal new and unanticipated pathogenic processes
that contribute to RA and might discover promising new
therapeutic targets.
MATERIALS AND METHODS
Study Subjects and Lymph Node Biopsy
Sampling
We included individuals with arthralgia and elevated IgM-
RF and/or ACPA levels, but without any evidence of arthritis
upon examination (RA-risk individuals, phase c/d; n = 8)
(3). The Median follow up time of these RA-risk individuals
was 20.4 months [9.8–35.6 (IQR)] and none of the RA-
risk individuals developed arthritis during this period. RA-risk
individuals were not allowed to have systemic or intra-articular
corticosteroid injection <28 days before enrolment. In addition,
RA patients with established disease based on fulfillment of
the American College of Rheumatology and European League
Against Rheumatism (ACR/EULAR) 2010 (39) criteria and
as assessed by the rheumatologist were included (n = 8).
Healthy individuals without any joint complaints and without
elevated IgM-RF and/or ACPA level and without active viral
infection or any history of autoimmunity or malignancy and
no present or previous use of disease-modifying antirheumatic
drugs (DMARDs), biologicals or other experimental drugs served
as control group (n = 8). IgM-RF was measured using IgM-RF
ELISA {Hycor Biomedical, Indianapolis, IN [ULN (upper limit of
normal) 49 kU/mL]} and ACPA was measured using anti-CCP2
ELISA CCPlus [Eurodiagnostica, Nijmegen, the Netherlands
(ULN 25 kAU/L)]. The study was performed according to
the principles of the Declaration of Helsinki, approved by
the institutional medical ethical review board of the Academic
Medical Centre, and all study subjects gave written informed
consent. All study subjects underwent an ultrasound-guided
inguinal LN needle core biopsy as previously described (40).
At the day of LN sampling none of the donors showed
signs of an infection. Table 1 shows the demographics of the
included subjects.
Lymph Node Stromal Cell Culture and
Stimulation
LNSC culture was performed as previously described (14, 16).
In short, using a 70µm cell strainer (BD Falcon, San Jose, CA)
lymphocytes were depleted and the remaining stromal tissue
of a freshly collected LN needle core biopsy was plated on
a 6-well culture dish (Greiner CELLSTAR R©, Sigma Aldrich,
Zwijndrecht, the Netherlands) (passage 0; P0) and complete cell
culture medium containing Dulbecco’s Modified Eagle Medium
(DMEM) low glucose (Gibco, Bleiswijk, the Netherlands)
supplemented with 0.1% penicillin (Astellas Pharma Inc., Leiden,
the Netherlands), 0.1% streptomycin, 0.05 mg/mL gentamicin,
10mM HEPES buffer, 2mM L-glutamine (all Gibco), and 10%
fetal calf serum (FCS) (GE Healthcare, Zeist, the Netherlands)
TABLE 1 | Demographic data of study subjects.
Healthy
controls
n = 8
RA-risk
individuals
n = 8
RA
patient
n = 8
Sex (female) (n) (%) 6 (75) 8 (100) 5 (63)
Age (years) [median (IQR)] 24 (23–32)* 47 (36–56) 43 (34–59)
IgM-RF positive (n) (%) 0 (0) 0 (0) 5 (63)
IgM-RF level (kU/l) [median
(IQR)]
— 3 (1–8) 34 (10–439)
ACPA positive (n) (%) 0 (0) 8 (100) 7 (88)
ACPA level (kAU/l) [median
(IQR)]
— 130 (44–274) 614 (72–1765)
IgM-RF and ACPA both
positive (n) (%)
0 (0) 0 (0) 5 (63)
DAS28 [median (IQR)] — — 4.4 (3.3–6.2)a
ESR (mm/h) [median (IQR)] — 5 (3–9) 16 (4–32)b
CRP (mg/l) [median (IQR)] 0.4 (0.3–0.9)a 1.3 (0.7–2.9) 14.7 (1.7–70.3)b
68TJC [median (IQR)] 0 (0) 1.5 (0.3–3) 8 (3–16.5)c
68SJC [median (IQR)] 0 (0) 0 (0) 2 (1–11)c
Treatment (n) (%) 5 (63)
• Corticoids
4 (50)
• NSAID
2 (25)d
• DMARD
3 (38)
• Failed TNF inhibitor
therapy
3 (38)
IgM-RF, IgM rheumatoid factor; ACPA, anti-citrullinated protein antibodies; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein; TJC, tender joint count; NSAID,
non-steroidal anti-inflammatory drug; DMARD, disease-modifying antirheumatic drugs.
aLevels missing from 2 individual.
bLevels missing from 4 individuals.
cLevels missing from 3 individuals.
dLevels missing from 3 individuals.
*Healthy controls are significantly younger than RA patients (P < 0.050, tested by
Kruskal–Wallis followed by a post Dunn’s test).
was added. Human LNSCs formed monolayers and were
expanded by passaging using trypsinization [0.05% trypsin,
5mM EDTA (Gibco)] in phosphate buffer saline (PBS, Fresenius
Kabi,‘s Hertogenbosch, the Netherlands) for 7min at 37◦C. For
harvesting, cells were washed with sterile PBS, trypsinized, and
the cell suspension was collected and centrifuged for 10min,
1,000 rpm (212 g) at 4◦C. Cells were then resuspended in
cold complete medium and counted using trypan blue (Sigma
Aldrich) in a Bürker-Türk chamber (LO Labor Optik, Lancing,
UK). As described previously, this ex vivo LNSC culture model
contains a mixture of FRCs and DNs (16). For the experiments,
cells were used between passages 4–8.
RNA Sequencing Analysis
RNA was isolated with the RNeasy kit (Qiagen) and used
for the generation of RNA libraries for sequencing with the
Illumina TruSeq R© Stranded total RNA preparation kit including
eukaryotic ribo-depletion by microsynth AG (Balgach, CH). The
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libraries were sequenced with the Illumina NextSeq500 high
output (1 × 75v2 instrument; >20 million reads per sample).
Data reads were quality-checked with FastQC. Bioinformatic
analysis included demultiplexing and trimming of Illumina
adaptor residuals, mapping of reads to hg38 reference genome
using STAR (2.5.1b), counting of mapped reads using HTSeq
(0.6.0), and statistical analysis using DESeq2 (1.6.3). Transcripts
with a p-value < 0.05, fold change ± 0.5, and expression >50
in all measured samples were considered as significantly changed
between the groups (Supplementary Table 3). Deconvolution of
the RNA-sequencing was performed in R (3.5.2) with CellMix
(1.6.2) package using the Frobenius semi-supervised learning
method (18). The gene signatures for each cell-type was retrieved
from a publicly available dataset (17). Rodda et al. listed 90
murine genes which represent the expression of the top 10 DEG
for all nine LN non-endothelial stromal cell clusters conserved
across samples (Supplementary Table 1). The conversion from
mouse to human nomenclature was done using biomaRt (version
Ensembl Genes 95 for human, Mouse strains 95 for mouse).
After the conversion, the gene selected for the stromal cell subset
present in our dataset had to have a logCPM >2.5 in at least
12 samples as cut-off (Supplementary Table 2). Subsequently, we
calculated the percentage of expressed gene signature present
per stromal cell subset. Cell type was selected for deconvolution
analysis if>60% of themurine genes of each list would be present
in our dataset (Supplementary Table 2).
Real-Time Cell Analyzer (RTCA)
Adhesion, spreading and proliferation was monitored with the
xCELLigence Real-Time Cell Analyzer DP system (Omni Life
Science). Cultured cells were detached with accutase (Sigma) and
seeded in 16 well E-Plates (Omni Life Science) in quadruplicates
(2,500 cells/well). The rate of proliferation was determined by
calculating the slope of the cell index (CI) curve in the interval
between 27 and 100 h after seeding.
Cell Proliferation Assay
Cells were detached with accutase and seeded in 96 well plates
(6000/well) in triplicates. After 48 and 96 h, respectively, Cell
counting kit-8 solution (Dojindo) was added and incubated
for 3 h before measuring the absorbance at 450 nm using a
microplate reader.
Contraction Assay
Cell contraction was measured in triplicates with a collagen-
based contraction assay (Cell Biolabs) according to the
manufacturers’ instructions. Briefly, 50,000 cells were seeded in
200 ul collagen mix and medium was added after 1 h. After 48 h,
gels were detached with a pipette tip. Pictures were taken after
20 h and the outline of the gel was measured with the AxioVision
Software (Zeiss). The ratio of the gel outline over the well outline
was taken as measure for the strength of the contraction.
Flow Cytometry Analysis
Human LNSCs were harvested from a 6-well dish using 1ml
TripLETM Select (Gibco) for 10min at 37◦C. Subsequently,
cells were washed in PBA buffer (PBS containing 0.01% NaN3
and 0.5% bovine serum albumin (BSA) (Sigma Aldrich), and
stained for 1 h with rat IgG2a anti-human Podoplanin (clone
NZ-1, AngioBio, Huissen, the Netherlands) on ice. Afterwards
cells were washed again in PBS buffer, followed by a second
incubation for 30min on ice protected from light using the
following directly labeled antibodies: Polyclonal goat anti-rat IgG
AlexaFluor647 (Invitrogen), CD45 FITC (clone HI30, Becton
Dickinson (BD) Pharmingen, Vianen, the Netherlands), HLA-
DR PE-Cy7 (clone L243, Sony Biotechnology, Surrey, UK) or
with corresponding isotype control antibodies. Staining with
HLA -ABC Pe-Cy7 (clone G46-2.6, Biolegend, London, UK)
served as a positive control and was used to set-up the correct
compensation configuration settings. Cells were measured on a
FACS CANTO II (BD) and data were analyzed using FlowJo
software 9.9.3 (Tree Star, Ashland, OR).
Illumina Methylation Arrays
DNA was isolated from cultured fibroblasts with the DNA
blood kit (Qiagen). DNA was converted by sodium bisulfite
modification and hybridized to Infinium Human methylation
450k arrays. The raw intensity data (IDAT) were imported
into R version 3.4.0 and processed using the minfi (1.22.1)
Bioconductor package. All the samples passed the mean
detection p-value of the minfi sample quality standard. Probes
from the X and Y chromosome were removed to exclude
sex variability. Individual beta-values for each sample were
calculated for further statistical analysis. Beta values are defined
as the ratio of methylated probe intensity and overall probe
intensity (sum of both unmethylated and methylated probe
intensity) (38).
Differential Methylation Analysis
The COHCAP algorithm was applied for the statistical analysis
of differentially methylated CpG sites and islands (41). A CpG
site was counted as methylated if the beta-value was >0.4 and
unmethylated if it was below 0.3. Differential methylated CpG
sites (DMS) in promoter regions (DMP) and/or CpG islands
that showed mean beta value differences of 0.1 and p-values
below 0.05 were defined as significantly differentially methylated
between the different conditions. Integrative Genome Viewer
(IGV) was used to visualize the DMS. Heatmaps were computed
using the entire set of significantly differentially methylated CpGs
between different conditions.
Pathway Analysis
Pathway analysis was performed using the “Investigate gene
sets” option in the Molecular Signature Database (MsigDB)
of the Broad Institute v6.1 (http://software.broadinstitute.org/
gsea/msigdb/annotate.jsp). Differentially expressed genes were
uploaded to compute significantly (FDR< 5%) enriched overlaps
with the canonical pathway (CP, KEGG, BioCarta, and Reactome)
collection in MsigDB.
Quantitative Real-Time PCR
Total RNA was isolated using the RNeasy Mini kit or
RNeasy Micro kit (Qiagen, Venlo, the Netherlands)
according to the manufacturer’s instructions, including a
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DNAse step to remove genomic DNA. Subsequently cDNA
was prepared using the RevertAid H Minus First Strand
cDNA Synthesis kit (Thermo Fisher Scientific, Landsmeer,
the Netherlands). Quantitative PCR was performed using
Taqman R© Universal PCR master mix combined with Taqman
assays (all from Applied Biosystems, Life Technologies,
Zwijndrecht, the Netherlands). For detection we used a
StepOnePlusTM Real-Time PCR System (Applied Biosystems).
Values for HLA-DRA (Hs00219575_m1) were corrected
by the expression level of 18S RNA (Hs99999901_s1). An
arbitrary calibrator sample was used for normalization. For
calculating the relative quantity (RQ) the delta-delta Ct method
was used.
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